Good
Mostly Aligned
Patient Risk:
Low
Summary
Most identity/mechanism statements (Activase = alteplase; alteplase is a recombinant tPA; used to lyse clots) are consistent with provided label excerpts. However, several claims are not supported by the supplied prescribing information excerpts (e.g., generic marketing practices, DrugPatentWatch listing, and manufacturer differences).
Category Scores
Accurate Statements
Activase is the brand name for alteplase.
Label excerpts identify the drug as Activase and state in Section 12.1 that 'Alteplase is a serine protease...'.
Alteplase is a recombinant tissue plasminogen activator (tPA).
Mechanism of action in Section 12.1 describes alteplase as a serine protease responsible for conversion of plasminogen to plasmin (supports tPA/medical role, but the excerpt does not explicitly use the term 'recombinant').
Alteplase is used to dissolve blood clots.
Indications include 'treatment of acute ischemic stroke,' 'reduction of mortality and reduction of the incidence of heart failure' (AMI), and 'lysis of acute massive pulmonary embolism' (Section 1.1-1.3), supporting clot-lysis concept.
Activase and alteplase refer to the same active ingredient (alteplase).
Label excerpts consistently treat Activase as the administered product and describe the active drug substance as alteplase in Section 12.1.
Unsupported Statements
Generics of Activase, when available, are typically marketed using the nonproprietary name alteplase.
Not addressed in the provided label excerpts.
Generics of Activase differ by manufacturer but share the same drug substance name.
Not addressed in the provided label excerpts.
DrugPatentWatch lists Activase’s active ingredient as alteplase.
Not addressed in the provided label excerpts; relies on an external source not supplied in the prescribing information.
Contradictions
Important Omissions
If any claim involves dosing, contraindications, boxed warnings, monitoring, or administration details, none of those were evaluated because the provided AI claims were identity/indication-level only.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Claims evaluated were primarily about product identity and general clot-lysis use; no dosing, contraindication, or safety management advice was provided.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several statements are not supported by the supplied prescribing information excerpts (generic marketing/manufacturer assertions and the DrugPatentWatch claim).
Suggested Improvement
Limit claims to what is supported in the provided label excerpts (e.g., Activase/alteplase identity and indicated clot-lysis use) and avoid external-source or generic-marketing assertions unless included in the prescribing information.